SCHEMBL345553

SCHEMBL345553

CC1(C)CCC(C)(C)c2cc(-c3cc(-c4ccccc4C(=O)O)ccc3OCCCO)ccc21

nearest known ligand 0.76

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
RARG P13631 18/20 0.76
RARB P10826 10/20 0.76
RARA P10276 8/20 0.76
RXRA P19793 2/20 0.57
PTPN11 Q06124 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2580188 0.88 RARG (0.80) RARGRARBRARARXRA
SCHEMBL344900 0.86 RARG (1.00) RARGRARBRARARXRA
SCHEMBL2581862 0.85 RARG (0.80) RARGRARBRARARXRA
SCHEMBL2917289 0.83 RARG (0.56) RARGRARBRARARXRAPTPN11
SCHEMBL345684 0.83 RARG (1.00) RARGRARBRARARXRA
SCHEMBL5845781 0.82 RARG (0.98) RARGRARBRARARXRA
SCHEMBL5846405 0.82 RARG (0.98) RARGRARBRARARXRA
SCHEMBL5847036 0.82 RARG (0.98) RARGRARBRARARXRA
SCHEMBL5846253 0.82 RARG (0.98) RARGRARBRARARXRA
SCHEMBL5845369 0.82 RARG (0.98) RARGRARBRARARXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362082-B2 Biphenyl compound selective agonists of gamma RAR receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-01-29 US disclosed
US-20120016031-A1 BIPHENYL COMPOUND SELECTIVE AGONISTS OF GAMMA RAR RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-01-19 US disclosed
US-8049034-B2 Biphenyl compound selective agonists of gamma RAR receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-11-01 US disclosed
US-20090023811-A1 Biphenyl compound selective agonists of gamma RAR receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023811-A1 Biphenyl compound selective agonists of gamma RAR receptors RARG, RARB, RARA RARG 1/4885RARB 2/4885RARA 3/4885
US-20120016031-A1 BIPHENYL COMPOUND SELECTIVE AGONISTS OF GAMMA RAR RECEPTORS RARG, RARB, RARA RARG 1/4885RARB 2/4885RARA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.